Informace o publikaci

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Autoři

SVATON Martin ZEMANOVA Milada SKŘIČKOVÁ Jana JAKUBÍKOVÁ Lenka KOLEK Vitezslav KULTAN Juraj KOUBKOVA Leona BEJCKOVA Alzbeta SALAJKA Frantisek HRNCIARIK Michal MELICHAR Bohuslav VRANA David KONECNY Marek CHLOUPKOVÁ Renata PESEK Milos

Rok publikování 2018
Druh Článek v odborném periodiku
Časopis / Zdroj Anticancer Research
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Doi http://dx.doi.org/10.21873/anticanres.13048
Klíčová slova Nivolumab; non-small cell lung cancer; overall survival; progression-free survival; biomarker
Popis Aim: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan Meier method and Cox analysis. Results: Among clinical parameters, histology was significantly associated with progression free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. Conclusion: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info